TACKLING CHRONIC LIVER DISEASE THROUGH

TACKLING CHRONIC LIVER DISEASE THROUGH

NASH, hepatitis, cirrhosis, liver failure, cancer.

Half a billion people worldwide are at risk unless new therapies are found.

About ContraVir

ContraVir is a biopharmaceutical company focused on the development of pleiotropic drug therapy for treatment of chronic liver disease. This therapeutic approach targets fibrosis and hepatocellular carcinoma (HCC) associated with non-alcoholic steatohepatitis (NASH), viral hepatitis, and other liver diseases. Our cyclophilin inhibitor, CRV431, is being developed to offer benefits to address these multiple complex pathologies.